Fatima Laher to HIV Envelope Protein gp120
This is a "connection" page, showing publications Fatima Laher has written about HIV Envelope Protein gp120.
Connection Strength
0,494
-
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. J Infect Dis. 2024 Aug 16; 230(2):e405-e415.
Score: 0,225
-
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378.
Score: 0,147
-
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk. J Infect Dis. 2022 08 24; 226(2):246-257.
Score: 0,049
-
HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens. Sci Rep. 2020 02 07; 10(1):2093.
Score: 0,041
-
Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol. 2016 04; 17:104-109.
Score: 0,031